CINCINNATI– LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of cardiovascular disease (CVD), today announced that the Board of Directors has appointed David Cory as Chief Executive Officer and a member of the Board of Directors, effective immediately. Evan Stein, MD, PhD, who has served as the CEO since co-founding LIB in 2015, will continue in a full-time operational role as Chief Operating Officer and Chief Scientific Officer.
Mr. Cory brings more than 30 years of leadership and operational experience in public and private, large pharma and emerging stage biotechnology companies, with an extensive commercial background spanning launches of global blockbuster products and targeted therapeutics for rare diseases, an established track record in the capital markets with over $1B+ raised and multiple companies which have successfully resulted in acquisition.
“We are pleased to welcome David as our new CEO and Board member,” said August Troendle, MD, LIB co-founder and Chairman of the LIB Board. “David’s track record and credibility in transforming private late-stage biopharma into public commercial companies makes him the ideal candidate for LIB and our late-stage lerodalcibep program.”
“With development of lerodalcibep close to completion and BLA submission planned for Q1 next year, David’s well-proven operating and commercial experience, combined with his drive and enthusiasm, is optimally suited to lead the company as it transitions to commercialization of lerodalcibep in the U.S, Europe, and rest of world,” said Evan Stein, MD, PhD, LIB co-founder and Board member.
David Cory said, “Lerodalcibep has a compelling clinical profile and differentiates itself in a growing PCSK9 inhibitor market which will approach $3 billion in 2023 and on target to reach or exceed $5 billion in 2025 when we anticipate approval and launch. I look forward to working with the LIB Board and the LIB operating team to make this exciting new therapy available for patients and healthcare providers in the future.”
